Dear Investors,

Join us for an in-person investor presentation on April 3rd at 5:30pm EDT to learn about AuraVax Therapeutics, Inc.—pioneering a first-in-class solution for respiratory viruses.

Why AuraVax Matters

AuraVax is developing NanoSTING, a groundbreaking broad-acting treatment and prevention for respiratory pathogens, including influenza, SARS-CoV-2, and RSV. Unlike existing treatments, NanoSTING works even against evolving strains and could protect high-risk populations like seniors, immunocompromised individuals, and those with chronic diseases.

Key Highlights

✅ First-in-Class: Broad-acting treatment for multiple respiratory viruses—unaffected by mutations.
✅ Biodefense + Public Health: Military and civilian applications unlock multiple funding sources.
✅ Accelerated Pathway: BARDA contract awarded for H5N1 vaccine candidate; part of the BARDA Vital Hub accelerator.
✅ Strategic Partnerships: Collaborating with Codagenix and Defender Pharmaceuticals to develop intranasal vaccines and military countermeasures.
✅ Market Potential: $20B addressable market with high growth potential.
✅ First Clinical Trials: Planned for 2026.

The Opportunity

Respiratory viruses cause over $25B in annual economic loss in the U.S. NanoSTING offers a unique dual-use solution for seasonal outbreaks and biodefense, ensuring military readiness and public health resilience.

Technology Pipeline

1. NanoSTING-001 – Targets mild-to-moderate infections in high-risk groups; potential for military biodefense applications under the FDA’s Animal Rule.
2. NanoSTING-002 – First-in-class mucosal adjuvant for intranasal vaccines, improving immunity and blocking transmission.

Investment Details

🔹 Raising $4.5M via SAFE
🔹 Minimum investment: $100K.
🔹 Potential Exit: Licensing NanoSTING to vaccine partners and for biodefense applications within 3–4 years.

Why Now

With dual-use potential and strategic government backing, AuraVax is positioned to disrupt a $20B+ market. Don’t miss the chance to be part of this high-growth opportunity.

Event Details – Limited to Select Investors

📍 Location: Fogo de Chão

1775 Tysons Blvd Suite 50,

Tysons, VA 22102

📅 Date: Thursday, April 3, 2025

🕔 Time: 5:30PM ET

⚠️ Exclusive Invite-Only Event – Seats Are Extremely Limited ⚠️

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to welcoming you for an evening of high-impact investing, powerful insights, and the future of prevention for respiratory pathogens.

Best regards,

Tien Wong

CEO

Opus8, Inc.